TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double genes deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL) subjects from our ATHENA trial (NCT06014073). Unexpectedly, expansion of the initial residual CD3-positive CAR T from products were measured in patients' peripheral blood (PB) without exception. Accompanying with host immune reconstitution and appearance of the detectable B cells, the CD3-positive allogenic CAR T cells exhibited a compelling amplification advantage over

Trial Details

NCT ID
NCT06323525
Phase
PHASE1 / PHASE2
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age 18-70 (inclusive).
  • Subjects who meet the following requirements:
  • 1 Histologically confirmed refractory/relapsed B cell NHL, including the following types defined by WHO 2016:
  • Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →